Print Print page     Email Email page

Investor Relations


MNTA - (NASD) $13.43   - 0.16 May 13, 2008 4:00 PM ET

Momenta is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company’s most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox®. Momenta’s first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company’s discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars’ functions in biological processes, with an initial focus in oncology.

Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.

View Annual Report and Proxy Material

Recent Releases

May 7, 2008
Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2008

May 1, 2008
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2008 Financial Results

View all releases »

Quotes delayed at least 20 minutes. Information provided by TurboFeed.